Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3275 participants.
Also called NCT03814187
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,275 participants
- Sponsor
- Registry
-
NCT03814187 -
2017-003092-55
-
- Other papers using this trial's data
- Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Denmark, Germany, Hungary, Netherlands, Poland, South Africa, Spain, Sweden, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03814187. Allocation not applicable; no masking; primary purpose treatment. Start 2019-04-16 (actual); primary completion 2023-02-13 (actual). Results posted on 2024-03-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
- Acronym
- ORION-8
- Condition
- ASCVD
- Condition
- Elevated Cholesterol
- Condition
- Heterozygous Familial Hypercholesterolemia
- Condition
- Homozygous Familial Hypercholesterolemia
- Intervention (Drug)
- Inclisiran Sodium
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct03814187- Content hash
4be60d494dc347868d1d617d1fd2d03bd6096d4fc648e364ba6b66936ad5cedb